EU indices slightly down | TA focus on GlaxoSmithKline


European stocks report | GlaxoSmithKline | Airbus | EssilorLuxottica | Julius Baer...

Downtrend 5

Friday, European stocks ended mixed. The Stoxx Europe 600 Index added 0.16%. Germany's DAX 30 gained 0.35%, the U.K.'s FTSE 100 rose 0.63%, while France's CAC 40 was down 0.31%.

45% of STOXX 600 constituents traded higher Friday.
70% of the shares trade above their 20D MA vs 71% Thursday (above the 20D moving average).
49% of the shares trade above their 200D MA vs 48% Thursday (above the 20D moving average).

The Euro Stoxx 50 Volatility index eased 1.23pt to 25.58, a new 52w high.

3mths relative high: Chemicals, Utilities
3mths relative low: Retail, Real Estate

Europe Best 3 sectors
automobiles & parts, basic resources, technology

Europe worst 3 sectors
travel & leisure, insurance, energy

The 10yr Bund yield fell 2bps to -0.47% (below its 20D MA). The 2yr-10yr yield spread rose 0bp to -22bps (above its 20D MA).

GE 07:00: Jun PPI YoY, exp.: -2.2%
GE 07:00: Jun PPI MoM, exp.: -0.4%
EC 09:00: May Current Account, exp.: E10.2B
FR 14:00: 12-Mth BTF auction, exp.: -0.56%
FR 14:00: 3-Mth BTF auction, exp.: -0.56%
FR 14:00: 6-Mth BTF auction, exp.: -0.55%

In Asian trading hours, EUR/USD eased to 1.1419 and GBP/USD slid to 1.2525. USD/JPY rebounded to 107.38. This morning, government data showed that Japan's exports declined 26.2% on year in June (-24.7% expected) and imports slid 14.4% (-17.6% expected).

Spot gold retreated to $1,807 an ounce.

GlaxoSmithKline, a pharmaceutical group, said it has signed a strategic collaboration agreement with biotechnology company CureVac for the development and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The company added: "GSK will make an equity investment in CureVac of £130m (E150m), representing close to a 10% stake, an upfront cash payment of £104m (E120m) and a one-time reimbursable payment of £26m (E30m) for manufacturing capacity reservation, upon certification of CureVac's commercial scale manufacturing facility currently under construction in Germany." From a chartist point of view, prices remain stuck within a mid term consolidation channel. The stock price is challenging its 20 and 50 DMAs. The RSI stands above 50% but lacks momentum. Above 1561p, the bias remains bullish. Next resistance thresholds are set at 1749p and 1857p in extension. A break below 1561p would call for a reversal down trend towards 1490p and 1415p.

Source: GAIN Capital, TradingView

Marks & Spencer, a retailing group, will announce hundreds of job cut this week due to the Covid-19, reported Sky News citing people familiar with the matter.

SSE, an energy company, was downgraded to "hold" from "buy" at Societe Generale.

Standard Life Aberdeen, an investment company, was downgraded to "underweight" from "equalweight" at Barclays.

Airbus, an aircraft manufacturer, said it has secured a 500 million pounds contract from the U.K. Ministry of Defence to build an additional satellite to support British military communications until at least 2040.

Natixis', a banking group, owner BPCE said it has no plan to acquire the remaining shares in the company, reported Bloomberg citing an emailed statement.

EssilorLuxottica, an eyewear conglomerate, announced that it has initiated legal proceedings before a Dutch district court to "obtain information from GrandVision. This is to assess the way GrandVision has managed the course of its business during the COVID-19 crisis, as well as the extent to which GrandVision has breached its obligations under the support agreement".

Teleperformance, an omnichannel company, was upgraded to "overweight" from "equalweight" at Morgan Stanley.

Intesa Sanpaolo, an Italian banking group, announced that it has raised is takeover offer for UBI Banca by adding an extra cash portion of 0.57 euro per share, representing about 652 million euros.

Julius Baer, a Swiss private bank, reported that 1H net income rose 43.2% on year to 491 million Swiss franc and operating income grew 8.9% to 1.85 billion Swiss franc. Also, assets under management fell 5.7% to 402 billion Swiss franc.

Enel: E0.168

More from Equities


This report is intended for general circulation only. It should not be construed as a recommendation, or an offer (or solicitation of an offer) to buy or sell any financial products. The information provided does not take into account your specific investment objectives, financial situation or particular needs. Before you act on any recommendation that may be contained in this report, independent advice ought to be sought from a financial adviser regarding the suitability of the investment product, taking into account your specific investment objectives, financial situation or particular needs.

GAIN Capital Singapore Pte. Ltd., may distribute reports produced by its respective foreign entities or affiliates within the GAIN Capital group of companies or third parties pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed to a person in Singapore who is not an accredited investor, expert investor or an institutional investor (as defined in the Securities Futures Act), GAIN Capital Singapore Pte. Ltd. accepts legal responsibility to such persons for the contents of the report only to the extent required by law. Singapore recipients should contact GAIN Capital Singapore Pte. Ltd. at 6826 9988 for matters arising from, or in connection with the report.

In the case of all other recipients of this report, to the extent permitted by applicable laws and regulations neither GAIN Capital Singapore Pte. Ltd. nor its associated companies will be responsible or liable for any loss or damage incurred arising out of, or in connection with, any use of the information contained in this report and all such liability is hereby expressly disclaimed. No representation or warranty is made, express or implied, that the content of this report is complete or accurate.

GAIN Capital Singapore Pte. Ltd. is not under any obligation to update this report.

Trading CFDs and FX on margin carries a high level of risk that may not be suitable for some investors. Consider your investment objectives, level of experience, financial resources, risk appetite and other relevant circumstances carefully. The possibility exists that you could lose some or all of your investments, including your initial deposits. If in doubt, please seek independent expert advice. Visit for the complete Risk Disclosure Statement.

Important Notice:

Cryptocurrencies are not legal tender currency and trading of derivatives on Cryptocurrencies are currently not covered under any regulatory regime in Singapore. Consequently, investors should be aware they do not have protection under the Securities and Futures Act (Cap. 289). Please ensure that you are fully aware of the risks.